NCT06760481

Phase I/Ib Trial of TIraGolumab, AtEzolizumab, and RadScopal Radiation in Patients With Advanced Solid Malignancies (TIGER)

• Status: Active Not Recruiting
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 7 (actual)
• Sponsor: M.D. Anderson Cancer Center · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

An open-label, Phase I/Ib study investigating the safety and efficacy of tiragolumab + atezolizumab + RadScopal™ XRT in patients with metastatic solid malignancies.

Detailed description

Primary Objectives: 1. To evaluate the safety of tiragolumab + atezolizumab + RadScopal™ XRT (Phase I). 2. To evaluate the efficacy of tiragolumab + atezolizumab + RadScopal™ XRT (Phase Ib). Secondary Objectives: 1. To compare the efficacy of tiragolumab + atezolizumab + RadScopal™ XRT to tiragolumab + atezolizumab and atezolizumab + RadScopal™ XRT. 2. To evaluate time-to-event outcomes of tiragolumab + atezolizumab + RadScopal™ XRT.

Conditions

• Advanced Solid Malignancies

Interventions

Type	Name	Description
DRUG	Tiragolumab	Given by IV
DRUG	Atezolizumab	Given by IV
RADIATION	Radiation Therapy	Given by IV

Timeline

• Start date: 2025-04-13
• Primary completion: 2028-09-15
• Completion: 2030-09-15
• First posted: 2025-01-06
• Last updated: 2026-04-15

Locations

1 site across 1 country: United States

Regulatory

• FDA-regulated drug study